What are Drug-drug Interactions Anyway?
A current buzz phrase in pharmaceutical research right now is “drug-drug interaction” or simply “drug…
Nathan Teuscher2011 年 1 月 5 日
The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain
ATP-binding cassette transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) have been shown to…
webdev2011 年 1 月 1 日
Absorption Rate
The rate at which a drug enters the body after administration is called the absorption…
Nathan Teuscher2010 年 12 月 30 日
What is a Half-life?
One of the most incorrectly used but most often quoted parameters is half life. The…
Nathan Teuscher2010 年 12 月 20 日
Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales
This article demonstrates techniques for describing and predicting disease progression in acute stroke by modeling…
webdev2010 年 12 月 1 日
Development of a Modeling Framework to Simulate Efficacy Endpoints for Motesanib in Thyroid Cancer Patients
To develop a modeling framework that simulates clinical endpoints (objective response rate and progression-free survival)…
webdev2010 年 11 月 1 日
Population Pharmacokinetic/Pharmacodynamic Modeling for the Time Course of Tumor Shrinkage by Motesanib in Thyroid Cancer Patients
To develop a population pharmacokinetic/pharmacodynamic model describing the relationship between motesanib exposure and tumor response…
webdev2010 年 11 月 1 日
A Pharmacokinetic/Pharmacodynamic Model for Cardiovascular Safety Assessment of R1551
Pharmacokinetic-pharmacodynamic relationships are crucial in understanding a drug's arrhythmogenic potential. Models assist to quantitatively relate…
webdev2010 年 8 月 21 日
Relationship Between Exposure to Sunitinib and Efficacy and Tolerability Endpoints in Patients with Cancer: Results of a Pharmacokinetic/Pharmacodynamic Meta-analysis
In this pharmacokinetic/pharmacodynamic meta-analysis, we investigated relationships between clinical endpoints and sunitinib exposure in patients…
webdev2010 年 7 月 1 日
